Evidence map›Paper›PMID 31619598›Full record

ArticleInternal medicine (Tokyo, Japan)2020

An ERG Gene Analysis in Two Cases with Metastatic Castration-resistant Prostate Cancer in Which Abiraterone Demonstrated Long-term Efficacy.

Tsuyoshi Yoshizawa, Kenya Yamaguchi, Nozomu Kawata, Hitomi Ryuzaki, Masahiro Ogawa, Daisuke Obinata, Junichi Mochida, Satoru Takahashi

Open access · diamondAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Internal medicine (Tokyo, Japan), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 79% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Tsuyoshi YoshizawaDepartment of Urology, Nihon University School of Medicine, Japan.
Kenya YamaguchiDepartment of Urology, Nihon University School of Medicine, Japan.
Nozomu KawataDepartment of Urology, Nihon University Hospital, Japan.
Hitomi RyuzakiDivision of Gastroenterology and Hepatology, Department of Medicine, Nihon University Hospital, Japan.
Masahiro OgawaDivision of Gastroenterology and Hepatology, Department of Medicine, Nihon University Hospital, Japan.
Daisuke ObinataDepartment of Urology, Nihon University School of Medicine, Japan.
Junichi MochidaDepartment of Urology, Nihon University School of Medicine, Japan.
Satoru TakahashiDepartment of Urology, Nihon University School of Medicine, Japan.
Nihon University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We analyzed the ERG gene status using fluorescence in situ hybridization (FISH) in two chemotherapy-naïve cases with metastatic castration-resistant prostate cancer (mCRPC) in which abiraterone demonstrated a long-term durable complete response. FISH identified Class 1 Edel and Class 2+ Edel in case 1, and Class 1 Edel in case 2. Our experience suggests that abiraterone may be effective in cases with mCRPC and ERG gene abnormalities, particularly Class 2+ Edel or Class 1 Edel. This is the first report of two cases with mCRPC that simultaneously investigated the ERG gene status and clinical aspects, including image evaluations and pathology.

Indexed as

AgedAndrostenesAntineoplastic Combined Chemotherapy ProtocolsHumansMaleMiddle AgedNeoplasm MetastasisPrednisoloneProstatic Neoplasms, Castration-ResistantTranscriptional Regulator ERGTreatment OutcomeAndrostenesERG protein, humanPrednisoloneTranscriptional Regulator ERGabirateronedurable complete responseERG genefluorescence in situ hybridizationmetastatic castration-resistant prostate cancer

Identifiers

PMID31619598
PMCPMC7028414
OpenAlexW2980599942

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.